Chronic Kidney Disease
Conditions
Interventions
Observation group:none
Control group:none
Sponsors
Guangdong Provincial People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age between 18 and 70 years, any gender; 2. Diagnosed with type 2 diabetes mellitus combined with chronic kidney disease, or kidney pathological diagnosis meets the criteria for DKD; 3. Estimated Glomerular Filtration Rate (eGFR) between 15 and 90 ml/min.1.73m^2 (including the lower limit); 4. 24-hour urinary protein amount >= 150mg, or urinary albumin-to-creatinine ratio (UACR) >= 30 mg/g, and at least 2 out of 3 tests conducted in the 3-6 months prior to enrollment are elevated; 5. Complete laboratory data and good follow-up compliance.
Exclusion criteria
Exclusion criteria: 1. Combined pregnancy; 2. High catabolic states such as infections, dehydration, hormonal therapy, etc.; 3. Acute complications of diabetes; 4. Severe liver disease (ALT and/or AST > 3 times the normal upper limit); 5. Combined malignant tumors or a history of tumor resection with a risk of recurrence; 6. Acute heart failure, or chronic heart failure with a New York Heart Association functional classification of Grade 3 or higher due to cardiomyopathy/valvular heart disease; 7. Gastrointestinal bleeding within the past month; 8. Clearly identifiable non-DKD factors such as primary glomerular diseases (e.g., acute glomerulonephritis, rapidly progressive glomerulonephritis), secondary glomerular diseases (e.g., lupus nephritis, purpura nephritis), acute interstitial nephritis (e.g., drug-induced kidney damage), obstructive nephropathy, etc.; 9. DKD combined with other glomerular diseases or tubular diseases; 10. perioperative period, myocardial infarction, paralyzed patients, coronary artery bypass grafting, patients with severe chronic obstructive pulmonary disease; 11. Patients with eGFR >= 15 ml/min/1.73m^2 who, due to their condition, are expected to initiate renal replacement therapy within 3 months; 12. Patients already enrolled in other clinical studies and currently under follow-up or medication.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| serum creatinine;estimated Glomerular Filtration Rate; | — |
Primary
| Measure | Time frame |
|---|---|
| End stage of kidney disease;Death; | — |
Countries
China
Contacts
Public ContactWenjian Wang
Guangdong Provincial People's Hospital
Outcome results
None listed